Short answer
Charles River Laboratories (CRL) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 28, 2026. Quarterly revenue was $996M (up 1.2% year over year) with net income of −$15M.
Q1 2026 key financials · XBRL
- Revenue
- $996M
- +1.2% YoY
- Net income
- −$15M
- −158.3% YoY
- Operating margin
- 12.0%
- EPS (diluted)
- −$0.30
- −160.0% YoY
Source: XBRL data from the Charles River Laboratories (CRL) Q1 2026 10-Q on SEC EDGAR. USD.
Charles River Laboratories Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $995.8M, up 1.2% YoY from $984.2M
- Operating margin 12.0% vs 7.6% YoY
- Manufacturing best performer: revenue $190.5M, up 6.8%; margin 24.6% vs (4.8)%
- RMS weakest revenue: $208.4M, down 2.2%; margin 23.9% vs 20.5%
- Operating cash flow $41.1M vs $171.7M; investing outflow $407.8M after $405.0M acquisitions
- Cautious client spending persisted in DSA; backlog held at $1.9B as of March 28, 2026
Risk Factors
- New cybersecurity incident: social engineering obtained credentials from a small number of employees
- Incident impact currently immaterial, with no material disruption or financial-system effect identified
- Regulatory and litigation exposure from potential data exfiltration, including privacy-law enforcement, fines, and civil claims
- AI-enhanced cyber threats increasing attack frequency and effectiveness
- Customer confidentiality risk: compromised study information could trigger contract terminations and reputational damage
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Charles River Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.